US ERA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROYECT ON AGENC WASHINGTON, D.C. LOUGE

008637

MEMORANDUM

277 KE 22 ESI CICES ANT TO LO SUEST/ ACES

医医院 衛星 计以下数字记录器

SUBJECT:

Kathon 8802 Biocide: Submission of an Acute

Inhalation Study in Rats; F(a)(2) Study.

TO:

Christine Rice/Tom Ayers

Product Mo ager (52)

Registration Division (HYDEST

FROM:

Linda L. Layle .. Toxicology Bran. If,

Health Effects Division

THRU:

K. Clark Swentzel Section II Head, Toxicology Branch II

Health Effects Division (H7509C)

and

19

Marcia van Gemert, Ph.D. Muan meet 10/15 Chief, Toxicology Branch II/HFAS/HED (H7509C)

Registrant: Chemical:

Rohm & Haas Company

5-chloro-2-methyl-4-isothiazolin-3-one and 2methyl-4-isothiazolin-3-one

Synchym:

Kathon 886F Biocide

Project No .: Caswell No .:

1-2349 195C

Record No .:

Case: 816020; Submission: S402232

Identifying No .:

107103-000707

MRID No .:

419635-01

Action Requested: Please review the tollowing 6(a)(2) study for methylisothiazolinone (chemicals 107103 and 107104).

Comment: There was no cover memo submitted to TB II with this study to explain why this acute inhalation study is being submitted. The study has been reviewed and the DER is attached.

Kathon 886F Biocide Acute Inhalation Toxicity Study in Rats, FJ Wanner and JV Hagan, dated July 10, 1991.

CONCLUSION: Under the conditions of the study, the LC for Kathon 8867 Biocide (containing 13.71 or 13.99% ai) is 2.36 mg/L (combined sexes). When calculated for active ingredient, which consists of two active ingredients (5-chloro-2-methyl-4-isothiazolin-3-one and

ż

2-mathyl-4-usothiazo m-3-one), the LC is 0.33 mg/L.

TOWNSHIP CATEGORY: Test material. ITT; active ingredient: II.

CLASSIFICATION: Core-supplementary. This study does not satisfy the guideline requirements (§31-.) for an adult inhalation toxidity study in rate, but it can be upgraded with the submission of dota/information on the percentage of the particles the vers of an MOTE: It is not clear to this reviewer any this is thought to be a 6 (a). I study when there are studies issted in the CASWELL file for this ai, which list the Toxidity Category as if the following the study does not present anything new and is not the referred or (a) (2) data, as defined in the UFR (153.66).

STUING THE PROPERTY OF THE PRO

Primary Reviewer: Linda L. Taylor, Ph.D Review Section II, Toxicology Branch II / HED (H7509C)

Sacondary reviewer: Y. Clark Swentzel Section Head, Review Section II, Toxicology Branch II / HED (H7509C)

008637

DATA EVALUATION REPORT

STUDY 1952: Acute Innal (tion-Rats (§81-3)

CASURVLE MUMBER: 1950

ME CO NUMBER: 419635-01

TEST M. ERILL: Kathon* 886F Biocide

5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-

isathlazolin-3-one

STUDY MIMEER: Pritical/Report # 91P-018

SECRICOS: Pohm and Haas Company

Spring House, PA

TASTING FASILITY: Toxicology Department, Rohm and Haas Company

Kathon* 886F Biocide Acute Inhalation Toxicity Study in WILLE OF BEBOEN.

ats

AUTHORISE: FI Wanner and JV Hagan

PIECEN ISSUED: July 10, 1991

WHELTY AND TYPES. A quality assurance statement was provided.

MOLUSION: Under the conditions of the study, the LC₅₀ for Kathon 886F Elocida (containing 13.71 or 13.99% ai) is 2.36 mg/L (combined sexes). the collaborated for active ingredient, which consists of two active ingredients (5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4isothia whim-3-one), the LC₅₀ is 0.33 mg/L.

TOXIC. Y CATEGORY: Test material: III; active ingredient: II.

CLASSIFIC, FION: Core-supplementary. This study does not satisfy the quideline 1 quirements (§81-3) for an acute inhalation toxicity study in rats, but it can be upgraded with the submission of data/information on the percentage of the particles that were \leq 1 um.

208637

T. MATERIALS

- Test compound: Kathon® 886F Biocide; Description: amber liquid; Batch #: Lot #'s J59098 (Group 1) and 50047 (Groups 2-6); Purity: 13.71% and 13.99°, respectively.
- Test animals: Species: rat; Strain: Crl:CD®BR; Age: not given; Weight: 184-230 grams (males)/193-230 grams (females); Source: Charles River-Kingston (Stone Ridge, NY).

II. METHODS

- Atmosphere Generation: The Kathon aerosol was generated by sing a single nebulizer for the three lowest dose levels, a second one for the next highest dose level, and a third one for the two highest dose levels. The test material was pumped into the nebulizer, and a compressed air source served to aerosolize a portion of the test material into the chamber intake. The various chamber concentrations were achieved by varying the dilution of the test material being fed into the nebulizer. In the multiple nebulizer chambers, the test material that was not aerosolized by the first nebulizer was drained into the second one, which further served to aerosolize the test material. The test material not aerosolized was directed to a waste container. The chamber was supplied with conditioned air drawn through an absolute filter located on the chamber air inlet. The chamber air flow rate, temperature, and humidity were monitored. For the highest exposure group, the chamber was operated at an airflow of 60 L/min, which gave a calculated 99% aerosol equilibrium time (t_{∞}) of 18.4 minutes, or less than 7.7% of the exposure duration. For the other 5 groups, the airflow rate was 75 L/min., which gave a calculated to of 14.7 minutes, or less than 6.1% of the exposure duration.
- B. Exposure: Six groups of rats (6/sex each) were exposed to an aerosol of the test material (see table below) during a single four-hour nose-only inhalation exposure period. There was no cont-ol group. The animals were randomly assigned and individually housed in suspended wire-mesh cages except during the exposure period. During exposure, animals were housed individually in nose-only restraining tubes (6" x 2" PVC pipe), which were placed into exposure 240-L Plexiglas® and stainless steel exposure chambers. Feed (Purina Rodent Laboratory Chow Checkers®) and water were available ad libitum, except during the exposure period. Atmospheric concentrations of the aerosol were determined 3 times during exposure. Particle size analysis was conducted twice during exposure using a QCM Cascade Impactor (California Measurements Inc., Sierra Madre, CA).

Conc.* (mg/L)	GROUP					
	1	2	3	4	5	- 6
a.i.	0.026	0.045	0.070	0.177	0.314	0 100
TM	0.19	0.32	0.05	1.26	2.24	3.02

- * a.i. = active ingredient; TM = test material
- C. Observations: Rats were examined for clinical signs of toxicity and mortality during exposure (unless the aerosol obscured observation), upon removal from the chamber, and then twice daily thereafter up to day 14 [exception: onc daily on weekends, Holidays and on Day 14 (terminal sacrifice)]. Body weights were recorded immediately prior to exposure, and on Days 1, 7, and 14 post dose. All surviving animals were necropsied on Day 14, and the following organs were examined macroscopically: adrenals, cervical lymph nodes, eyes, gonads, heart, intestinal tract, kidneys, liver, lungs, pancreas, salivary glands, spleen, stomach, thymus, thyroids, trachea, urinary bladder, and uterus.

III. RESULTS

A. <u>Atmosphere Generation</u>: Exposure to the various test material concentrations occurred on 6 different days. A summary of the results is shown below.

Group	Nom.conc. (mg/L)	Anal. conc. (mg/L)	Pa MMD* (Jim)	rticle Size GSD**	RF (%)***
11	4.3	0.19	1.5	4.4	
2	5.3	0.32	2.4	3.9	66
3	4.3	0.50	2.2		58
4	10.8	1.26		4.1	58
5	13.2	2.24	4.0	4.5	44
			. 3.5	3.2	4.8
	13.4	3.02	2.6	2.7	66

*Mass Median Diameter; ** Geometric Standard Deviation;
***Respirable Fraction

Calculation of the mass median diameter (MMD) and the geometric standard deviation (GSD) was performed by computer using a log-probit regression analysis program (Hagan, 1980). The respirable fraction was calculated from the MMD and the GSD using the RFB program (Moss & Baldwin, 1983), which defines "respirable fraction" as that fraction of an aerosol that would pass a size-selector described by the American Conference of Governmental Industrial Hygienists (ACGIH), with the following characteristics: 90% of \leq 2.0 μm particles, 75% of 2.5 μm

particles, 50% of 3.5 um particles, 25% of 5.0 um particles, and o% of \geq 10 um particles will pass through the selector. NOTE: There is no information on what percent of the particles were \leq 1 um.

B. Animal Observations: Mortality was observed as shown below. Signs of respiratory irritation, including rales, gasping, hyperpnea, dyspnea, and vocalization were observed in some animals of all groups immediately after exposure, with the number of animals displaying signs and the severity increasing with increasing dose. The signs of respiratory irritation disappeared within 2 to 12 days in all survivors. Additionally, small red droplets (expired nasal exudite) were observed in the cages of the animals in the 4 highest dose groups, which was considered to be the result of nasal irritation; the irritation disappeared within 6-12 days in all survivors. All other signs were unrelated to treatment.

GROUP	Mortalities		vivors
		Males	Females
1	0/12	6/6	5/6
2	1/12	6/5	5/5
3	0/12	6/6	5/6
4	3/12	5/6	4/6
5	4/12	3/6	5/6
6	9/12	0/5	3/6

Body Weight and Body-Weight Changes

All dose groups lost weight during/after exposure, with the Da; 1 body weight being 2-15% lower than that measured prior to treatment. With the exception of the highest dose group animals, all animals had gained weight by the next weighing period (Day 7). None of Group 6 males survived to Day 7. Group 6 females had not attained their starting body weight by Day 7; by day 14, there was a gain of 23 grams.

GROUP	Overall Body-Weight Gain (g) MALES FEMALES			
1	125	63		
2	113	25		
3	120	23		
4	124	33		
5	111	53		
6	_	23		

Gross Pathology

The only treatment-related observation was the occurrence of gas in the stomachs and/or intestines of the three highest dose groups, which was attributed by the author to be the result of swallowing air in an attempt to breath.

LC₅₀ Calculation

The LC_{50} for the test material (combined sexes) was 2.36 mg/L, with confidence limits of 1.60 to 4.82 and a slope of 2.2. With respect to the active ingredient, an LC_{50} of 0.33 mg a.i./L was calculated, with confidence limits of 0.22 to 0.67, and a slope of 2.2.

IV. CONCLUSIONS

The LC_{50} for Kathon 886F Biocide (containing 13.71 or 13.99% ai) is 2.36 mg/L (combined sexes). With respect to the active ingredient, which consists of two active ingredients (5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one), the IC_{50} is 0.33 mg/L.

age	s through are not included.
• •	
	material not included contains the following type or rmation:
·	Identity of product inert ingredients.
	Identity of product impurities.
	Description of the product manufacturing process.
. :	Description of quality control procedures.
	Identity of the source of product ingredients.
····	Sales or other commercial/financial information.
	A draft product label.
	The product confidential statement of formula.
/	Information about a pending registration action.
$\sqrt{}$	FIFRA registration data.
	The document is a duplicate of page(s)
	The document is not responsive to the request.